Treating Early HER2+ Breast Cancer: KATHERINE

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02Подробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Treating Early HER2+ Breast Cancer: KRISTINEПодробнее

Dr. Crew on Treatment in Favorable-Risk HER2+ Breast CancerПодробнее

Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast CancerПодробнее

Treatment for High- and Low-Risk HER2+ Breast CancerПодробнее

KATHERINE trial updates for HER2-positive breast cancerПодробнее

Expert Discusses Practice-Changing Data from KATHERINE Trial in Breast CancerПодробнее

KATHERINE Trial: T-DM1 cuts HER2-positve invasive breast cancer recurrenceПодробнее

Phase III KATHERINE Clinical TrialПодробнее

KATHERINE trial tests trastuzumab emtansine in breast cancer recurrenceПодробнее